DERMATOP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DERMATOP (DERMATOP).
Prednicarbate is a corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
| Metabolism | Prednicarbate is metabolized primarily in the skin via hydrolysis to inactive metabolites; systemic metabolism follows pathways typical of corticosteroids. |
| Excretion | Primarily hepatic metabolism with inactive metabolites; <10% excreted renally as unchanged drug; minimal biliary/fecal elimination. |
| Half-life | Terminal elimination half-life: approximately 100 hours (range 68-120 hours) following topical administration; prolonged accumulation with chronic use due to high lipophilicity and slow release from skin depot. |
| Protein binding | Prednisolone (active metabolite) is 70-90% bound to albumin and corticosteroid-binding globulin (CBG); prednicarbate itself is highly protein-bound (>95%). |
| Volume of Distribution | Apparent Vd: Not well characterized for topical route; for systemic corticosteroids, Vd is approximately 0.5-1.0 L/kg, indicating extensive tissue distribution; clinical meaning: large Vd reflects high lipophilicity and tissue uptake. |
| Bioavailability | Topical: Percutaneous absorption 1-5% in normal skin; increased to 10-30% in inflamed or damaged skin; systemic bioavailability is minimal with intact skin but can be significant with occlusive dressings or widespread use. |
| Onset of Action | Topical: Improvement noted within 1-2 weeks of regular application; maximal effect by 3-4 weeks. |
| Duration of Action | Duration: Sustained anti-inflammatory effect persists for several days to weeks after discontinuation due to skin reservoir; clinical remission may last weeks to months. |
| Molecular Weight | 392.46 |
Apply a thin layer to affected skin areas twice daily (morning and evening) for up to 4 weeks. Do not use more than 50 g per week.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment; topical application results in negligible systemic absorption. |
| Liver impairment | No specific dose adjustment guidelines available; use caution in severe hepatic impairment due to potential systemic effects. |
| Pediatric use | For children ≥2 years: Apply a thin layer to affected areas twice daily; maximum treatment duration is 4 weeks. Avoid use in children <2 years due to increased risk of systemic absorption. |
| Geriatric use | No specific dose adjustment; use the lowest effective dose for the shortest duration due to increased skin fragility and potential for systemic absorption. |
| 1st trimester | No adequate studies in pregnant women; use only if potential benefit justifies potential risk to fetus. Corticosteroids are known to be teratogenic in animals. |
| 2nd trimester | Same as t1; caution advised. Prolonged use may lead to fetal growth restriction. |
| 3rd trimester | May cause maternal hypothalamic-pituitary-adrenal suppression; avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for DERMATOP (DERMATOP).
| Placental transfer | Corticosteroids cross the placenta. Systemic absorption from topical use is minimal but may occur with high doses or extensive application. |
| Breastfeeding | Topical application likely results in negligible systemic absorption; however, avoid application to breast area to prevent infant ingestion. Use with caution, especially on large areas or for prolonged periods. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to prednicarbate or any componentViral skin infections (e.g., herpes, varicella)Fungal skin infectionsTuberculous skin lesionsSyphilitic skin lesionsPerioral dermatitisRosacea
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria may occur with extensive use, Local irritation, atrophy, and allergic contact dermatitis may develop, Use in children should be limited to the smallest amount necessary due to increased susceptibility to systemic effects |
| Food/Dietary | No known food interactions with topical prednicarbate. Systemic interactions unlikely due to minimal absorption. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C. Prednisolone is a corticosteroid; animal studies show increased risk of cleft palate at high doses. First-trimester exposure may be associated with a small increased risk of oral clefts. Chronic use in second/third trimester may cause fetal adrenal suppression. Limited human data; benefit must outweigh risk. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, serum electrolytes, and signs of infection. Fetal monitoring includes ultrasound for growth restriction if chronic use. Assess fetal adrenal function if maternal use prolonged near term. |
| Fertility Effects | Corticosteroids may suppress hypothalamic-pituitary-adrenal axis, potentially causing menstrual irregularities and impaired fertility. Effects are reversible upon dose reduction or discontinuation. |
| Clinical Pearls | Dermatop (prednicarbate) is a topical corticosteroid of medium potency. Avoid use on face, intertriginous areas, or with occlusive dressings without clinical necessity. Monitor for skin atrophy, striae, and systemic absorption especially in children or widespread use. Discontinue if irritation or infection develops; use concomitant antifungal/antibacterial if needed. |
| Patient Advice | Apply a thin layer to affected skin only, avoiding eyes, mouth, and open wounds. · Wash hands after application unless treating hands. · Do not cover treated area with bandages or wraps unless directed by your doctor. · Use only for prescribed duration; overuse can cause skin thinning and other side effects. · Inform your doctor if you develop redness, swelling, or signs of skin infection. |